The Industrial Ecosystem Continues to Improve,GF CSI Medical Service ETF(560260) Rises 2.12% Intraday

NewTimeSpace News: As of 13:19 on March 27, 2026, the CSI Medical Service Index (399989) surged 2.54%. Among its constituent stocks, Hotgen Biotech rose 17.29%, Joinn Laboratories (China) Co.,Ltd. jumped 10.00%, and Zhejiang Jiuzhou Pharmaceutical Co.,Ltd. climbed 4.62%. China Stem Cell Group Co.,Ltd., Boteng Co.,Ltd. and other stocks followed the upward trend. GF CSI Medical Service ETF(560260) advanced 2.12% to close at RMB 0.82. (The stocks listed above are only constituent stocks of the index and do not constitute any specific investment recommendation.)

In terms of liquidity, GF CSI Medical Service ETFrecorded an intraday turnover rate of 0.14% with a trading volume of RMB 2.1234 million. Over a longer time frame, as of March 26, the average daily trading volume of GF CSI Medical Service ETFstood at RMB 12.7831 million in the past year.

In terms of scale, the latest size of GF CSI Medical Service ETFreached RMB 1.485 billion. (Data source: Wind)

In terms of capital inflow, the latest capital inflow and outflow of GF CSI Medical Service ETFwere balanced. Over a longer time frame, there were 3 days of net capital inflow in the past 5 trading days, with a total net inflow of RMB 25.7553 million and an average daily net inflow of RMB 5.1511 million. (Data source: Wind)

In terms of earnings capacity, as of March 26, 2026, since its inception, GF CSI Medical Service ETFhas achieved a maximum monthly return of 29.94%, a longest consecutive monthly gain of 5 months with a cumulative increase of 24.01% during the period, and an average return of 6.78% in rising months. As of March 26, 2026, GF CSI Medical Service ETFhas an annualized excess return over the benchmark of 1.44% since its establishment.

In terms of drawdown, as of March 26, 2026, GF CSI Medical Service ETFhad a relative drawdown of 0.04% against the benchmark since the beginning of the year, with a relatively low drawdown risk among comparable funds.

In terms of fees, GF CSI Medical Service ETFhas a management fee rate of 0.50% and a custodian fee rate of 0.05%, with its fee level standing at a relatively low range among comparable funds.

In terms of tracking accuracy, as of March 26, 2026, the tracking error of GF CSI Medical Service ETFwas 0.009% in the past month, ranking the highest in tracking accuracy among comparable funds.

From a valuation perspective, the latest Price-to-Earnings Ratio Trailing Twelve Months (PE-TTM) of the CSI Medical Service Index, which GF CSI Medical Service ETFtracks, is only 28.13 times, at the 0.76th percentile of the past year. That is, the valuation has been lower than the level seen in more than 99.24% of the time over the past year, standing at a historically low level.

GF CSI Medical Service ETFclosely tracks the CSI Medical Service Index, which selects listed company securities in the medical and health industry engaged in medical device manufacturing, medical services, medical informatization and other medical-themed businesses as index samples, reflecting the overall performance of medical-themed listed company securities.

Data showed that as of February 27, 2026, the top 10 weight stocks of the CSI Medical Service Index (399989) were WuXi AppTec, Mindray Bio-Medical Electronics Co.,Ltd., United Imaging Healthcare, Aier Eye Hospital Group, Tigermed Consulting Co.,Ltd., Pharmaron Beijing Co.,Ltd., Lepu Medical Technology (Beijing) Co.,Ltd., Jiangsu Yuyue Medical Equipment&Supply Co.,Ltd., Meinian Onehealth Healthcare Group Co.,Ltd. and Bloomage Biotech Co.,Ltd. in turn, accounting for a total of 50.56% of the index weight. (The stocks listed above are only constituent stocks of the index and do not constitute any specific investment recommendation.)

WINNING HEALTH Technology Group Co.,Ltd. stated that the construction and improvement of an intelligent-driven healthcare ecosystem will lay a solid foundation for improving the efficiency, quality and accessibility of medical services, optimizing resource allocation, reducing medical costs, and realizing patient-centered, inclusive, personalized and precise medical services.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.